News and Trends 26 Oct 2022 Scancell signs agreement with Genmab Scancell Holdings plc, the developer of novel immunotherapies for the treatment of cancer and infectious disease, has signed a licensing agreement with Genmab, an international biotechnology company, to develop and commercialize a Scancell investigational anti-glycan monoclonal antibody into novel therapeutic products. Genmab has been granted the exclusive right to develop and commercialize the Scancell antibody […] October 26, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2022 New UK spinout VacV Biotherapeutics emerges from stealth to work on cancer immunotherapies VacV Biotherapeutics, a cancer immunotherapy company developing innovative viral-based therapies, emerged from stealth mode today to advance its pipeline of pre-clinical assets with best-in-class potential, towards the clinic. VacV Biotherapeutics has spun out of Barts Cancer Institute and Queen Mary University of London following 20 years of research by immunotherapy experts Yaohe Wang, Nicholas Lemoine, […] October 26, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2022 Inotrem study for the treatment of critically ill COVID-19 patients meets endpoints Inotrem has announced positive results for ESSENTIAL, its phase II clinical trial in COVID-19 patients hospitalized in critical care units and experiencing acute respiratory distress. The French clinical stage biotech company specializes in immunotherapies for acute and chronic inflammatory syndromes. The announcement was made at the European Society of Intensive Care Medicine’s Annual Congress, held […] October 26, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2022 Recursion announces $150M private placement U.S. biotech Recursion Pharmaceuticals has entered into a stock purchase agreement for the sale of an aggregate of approximately 15.3 million shares of its Class A common stock in a private placement. It was led by Kinnevik AB, with participation by Baillie Gifford, Mubadala Investment Company, Laurion Capital Management, Invus, and Platinum Asset Management. The […] October 26, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2022 Almaden Genomics launches g.nome platform Almaden Genomics has launched g.nome, a cloud-native platform designed to streamline genomic workflows and accelerate genomic discovery. Leveraging a visual drag-and-drop workflow builder and curated library of toolkits, Almaden Genomics said g.nome enables users to have confidence in their results, get to market faster and scale their business profitably. The g.nome platform condenses bioinformatic pipeline […] October 26, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2022 ABL and RD-Biotech to partner on cell and gene therapy manufacturing French companies ABL and RD-Biotech have signed a strategic partnership to cover cell and gene therapy (C>) GMP manufacturing. ABL, is a contract development and manufacturing organization (CDMO) that specializes in the development and manufacturing of solutions for biopharma, including viruses for gene therapies, oncolytic viruses and vaccine candidates. RD-Biotech is a CRO (contract research […] October 26, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 25 Oct 2022 Watch: NLS Days NLSInvest award winners – Asgard Therapeutics The two biotech start-up companies MyoPax and Asgard Therapeutics won first and second prize at NLSINvest Awards, out of 40 companies that participated in Nordic Life Science Days’ start-up pitching challenge. 40 selected Nordic start-up companies attended Nordic Life Science Days, the largest partnering conference for life sciences in the Nordics, which was held in […] October 25, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Opinion 25 Oct 2022 Precision medicine research must lose its Eurocentricity Precision medicine research relies on genetic testing at scale, but how do we reach more diverse patient populations and collect nationally representative samples? Patrick Short, CEO and co-founder of Sano Genetics, and Natasha Ratcliffe, director of community engagement and partnerships at Couch Health, explain how Eurocentricity is holding back genetics, and what can be done. […] October 25, 2022 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 25 Oct 2022 Delayed release tablets to treat ulcerative colitis launched in Canada With Canada having one of the highest incidences of ulcerative colitis in the world, the recent launch of Tillotts Pharma AG’s Octasa 800 mg will be well-received. Tillotts is part of the Japanese Zeria Group, and announced Octasa (mesalazine) delayed-release tablets, as first-line treatment for moderately active ulcerative colitis (UC) in Canada. The launch, the […] October 25, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 25 Oct 2022 Distributor of Curcugen and Ginfort receives dual natural product licenses Two Health Canada natural product licenses have been achieved by DolCas Biotech LLC and have been found safe, effective and high quality. The products are its concentrated turmeric extract, Curcugen, and the other for Ginfort, a powerful ginger extract in powdered format. Produced by Olene Life Sciences, the two ingredient brands are research-backed for clinical […] October 25, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2022 Beckley Psytech acquires Eleusis Therapeutics Beckley Psytech Limited has entered into a definitive agreement to acquire clinical-stage life science company Eleusis Therapeutics Limited in an all equity transaction. Under the terms of the agreement, which has been approved by shareholders, Beckley Psytech has acquired 100% of Eleusis, receiving full developmental and commercial rights for the company’s assets, which will further […] October 24, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2022 Syncona to acquire Applied Genetic Technologies Corporation Healthcare company Syncona Limited says its newly established portfolio company has agreed to acquire, by a tender offer, all outstanding shares of Applied Genetic Technologies Corporation (AGTC). AGTC is a clinical-stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an […] October 24, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email